Introduction:
Samsung BioLogics announced that it has entered into US$148 Million manufacturing contract for its Plant 3 facility.
Features:
The Plant 3 facility has a total capacity of 180,000 liters and is expected to be cGMP operational by the fourth quarter of 2018.
The products from the plant 1 (6 x 5,000 L) and Plant 2 (10 x 15,000 L) facilities mature, Plant 3 will be utilised to supply satisfy the demand of clients.
The third plant, which was completed in November, is the world’s biggest single-site biologics drug manufacturing facility.
It will go online in 2020 and is expected to have the world’s largest capacity for a biologics contract manufacturing organisation, with total production capacity hitting 362,000 liters.
Adding of 18, 000L of stainless steel bioreactor capacity effectively doubles the total capacity across Samsung BioLogics other two plants.
The plant expansion plans focus on progress made in the development of Alzheimer’s disease therapies.
Specifications:
| Name | Samsung BioLogics |
| Location | South Korea |
| Type | Manufacturing Contract |
| Parties Involved | Samsung BioLogics |
| Budget | US$148 Million |
